These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33432321)

  • 21. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
    Won JH; Lee H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data science in unveiling COVID-19 pathogenesis and diagnosis: evolutionary origin to drug repurposing.
    Kumar Das J; Tradigo G; Veltri P; H Guzzi P; Roy S
    Brief Bioinform; 2021 Mar; 22(2):855-872. PubMed ID: 33592108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combating devastating COVID-19 by drug repurposing.
    Pawar AY
    Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated Bioinformatics Analysis for the Screening of Associated Pathways and Therapeutic Drugs in Coronavirus Disease 2019.
    Wang T; Zhao M; Ye P; Wang Q; Zhao Y
    Arch Med Res; 2021 Apr; 52(3):304-310. PubMed ID: 33309308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
    Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
    PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
    Watashi K
    Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential drug development and therapeutic approaches for clinical intervention in COVID-19.
    Dowarah J; Marak BN; Yadav UCS; Singh VP
    Bioorg Chem; 2021 Sep; 114():105016. PubMed ID: 34144277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.
    Khan M; Adil SF; Alkhathlan HZ; Tahir MN; Saif S; Khan M; Khan ST
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic targets and potential agents for the treatment of COVID-19.
    Wu Y; Li Z; Zhao YS; Huang YY; Jiang MY; Luo HB
    Med Res Rev; 2021 May; 41(3):1775-1797. PubMed ID: 33393116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug repurposing against SARS-CoV-2 using computational approaches.
    Kumar S; Kovalenko S; Bhardwaj S; Sethi A; Gorobets NY; Desenko SM; Poonam ; Rathi B
    Drug Discov Today; 2022 Jul; 27(7):2015-2027. PubMed ID: 35151891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.
    Forchette L; Sebastian W; Liu T
    Curr Med Sci; 2021 Dec; 41(6):1037-1051. PubMed ID: 34241776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates.
    Serafim MSM; Gertrudes JC; Costa DMA; Oliveira PR; Maltarollo VG; Honorio KM
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33624754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
    Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
    Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics.
    Saleemi MA; Ahmad B; Benchoula K; Vohra MS; Mea HJ; Chong PP; Palanisamy NK; Wong EH
    Infect Genet Evol; 2020 Nov; 85():104583. PubMed ID: 33035643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
    Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E
    J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.